Akston Biosciences Corp — Form D/A
Akston Biosciences Corp of BEVERLY, MA, a company, filed a Form D amendment with the SEC on 2021-06-09. The offering totals $8.0M, of which $7.9M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-06-09
- Form: D/A
- Accession: 0001776612-21-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $8.0M
- Amount sold: $7.9M
- Remaining: $123K
- Investors: 71
- Date of first sale: 2020-12-17
- Revenue range: Decline to Disclose
- SEC file number: 021-384848
Issuer
- Name: Akston Biosciences Corp
- CIK: 0001776612
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 100 CUMMINGS CENTER SUITE 454C, BEVERLY, MA, 01915
- Phone: 978-969-3381
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| James M Herriman | Executive Officer | BEVERLY, MA |
| Thomas M Lancaster | Director | BEVERLY, MA |
| Thomas M Lancaster | Executive Officer | BEVERLY, MA |
| Lovick E Cannon | Director | BEVERLY, MA |
| Todd C Zion | Director | BEVERLY, MA |
| Todd C Zion | Executive Officer | BEVERLY, MA |
| Robyn M Davis | Director | BEVERLY, MA |
Other filings by this issuer (5)
More